New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
20:25 EDTJASO, JASO, LMIA, LMIA, STRL, STRL, TNP, TNP, APRI, APRI, HNR, HNR, INO, INONotable companies reporting before Monday's open
Notable companies reporting before Monday's market open, with earnings consensus, include Apricus Biosciences (APRI), consensus (6c); Harvest Natural Resources (HNR), consensus 10c; Inovio Pharmaceuticals (INO), consensus (3c); JA Solar Holdings (JASO), consensus 1c; LMI Aerospace (LMIA), consensus 4c; Sterling Construction (STRL), consensus ($1.47); and Tsakos Energy Navigation (TNP), consensus (9c).
News For APRI;HNR;INO;JASO;LMIA;STRL;TNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
09:53 EDTJASOCredit Suisse Events at Solar Power International
Credit Suisse holds meetings in Las Vegas in conjunction with the Solar Power International Conference include ENPH, TSL, CSIQ, SCTY, JASO, HSOL and STRI on October 22.
October 21, 2014
07:08 EDTJASOUBS to hold meetings at Solar Power International
Meetings at Solar Power International are being held in Las Vegas on October 21-23.
06:10 EDTINOInovio, MedImmune, UPENN awarded $12.2M collaborative study by DARPA
Inovio Pharmaceuticals (INO) announced the Defense Advanced Research Projects Agency, or DARPA, has awarded $12.2M for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of Pennsylvania; Inovio Pharmaceuticals; and MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The group will develop DNA-based monoclonal antibodies, or mAbs, for infectious disease treatment. DARPA is an agency of the US Department of Defense that creates and supports novel technologies important for national security. Together, the three organizations will develop and assess the DNA mAbs in preclinical studies using technology developed by Penn and licensed by Inovio. The collaboration will focus on three disease areas – influenza virus, Pseudomonas aeruginosa and Staphylococcus aureus.
October 20, 2014
07:48 EDTLMIALMI Aerospace awarded contracts to supply parts for Gulfstream business jets
Subscribe for More Information
06:13 EDTAPRIApricus Biosciences to host conference call
Subscribe for More Information
05:27 EDTAPRIApricus licensed U.S. development, commercialization rights for fispemifene
Apricus Biosciences announced that it has licensed the U.S. development and commercialization rights for a novel selective estrogen receptor modulator, or SERM, fispemifene, an investigational treatment for urological conditions in men, from Forendo Pharma, a private therapeutics company based in Finland. This license agreement combines Apricus' expertise in men's health with Forendo's established leadership in SERM drug discovery, to advance the development of fispemifene as an investigational treatment for urological conditions in men. Under the terms of the agreement, Forendo and its advisors received an upfront license fee of $12.5M comprised of a $5M cash payment and the issuance of $7.5M in Apricus common stock; approximately 3.6M shares priced at the 360-day average market price of $2.08 per share. The agreement includes additional potential clinical and regulatory milestone payments to Forendo of up to $45M, including for potential FDA approval, as well as potential commercial milestone payments totaling up to $260M, based on achieving specified annual net sales levels up to $1B in the U.S. Apricus will also pay tiered low double-digit royalties based on net sales once the product is commercialized. Apricus will be responsible for the clinical development of fispemifene in the U.S., as well as all future commercialization efforts in the U.S. and its territories.
October 16, 2014
08:45 EDTTNPTsakos Energy comments on market conditions
Subscribe for More Information
October 15, 2014
11:27 EDTINOOptions with decreasing implied volatility
Options with decreasing implied volatility: EXAS INO ATLS LOCO OPK INFY EUO FDO
October 14, 2014
06:42 EDTJASOPV modules with solar-grade wafers to account for 89% of capacity, DigiTimes says
Solarbuzz says solar photovoltaic modules using solar-grade wafers will account for 89% of solar capacity forecast to be installed in 2014, reports DigiTimes. Thin-filmed panel makers will supply nearly 8% of end-market demand in 2014, while premium cyrstalline silicon suppliers making up the remaining 3% share. Publicly traded companies in the space include Canadian Solar (CSIQ), First Solar (FSLR), JA Solar (JASO), SunPower (SPWR), Trina Solar (TSL), Panasonic (PCRFY) and Yingli Green Energy (YGE). Reference Link
October 13, 2014
07:13 EDTAPRIApricus Biosciences awarded U.S. patent for RayVa
Apricus Biosciences announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application Serial Number 14/110,348. The patent application generally is directed to methods and compositions for treating Raynaud's phenomenon, including claims related to treating Raynaud's phenomenon that is secondary to systemic sclerosis. Raynaud's phenomenon secondary to systemic sclerosis affects an estimated three to five percent of people in the U.S., disproportionately affecting women and currently has no approved therapy in the U.S., representing an unmet medical need. The FDA has indicated that Apricus' RayVa™ product may qualify for priority review, given the unmet medical need and lack of approved products to treat secondary Raynaud's phenomenon. The FDA will determine if the RayVa New Drug Application qualifies for priority review following its submission, which could occur as early as 2017.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use